It is prescribed for adults across mild, moderate, and severe stages, with treatment aimed at supporting memory, attention, and daily functioning by increasing acetylcholine activity in the brain.
It is prescribed for adults across mild, moderate, and severe stages, with treatment aimed at supporting memory, attention, and daily functioning by increasing acetylcholine activity in the brain.
Donepezil, the active ingredient of Aricept, is a centrally acting cholinesterase inhibitor used for cognitive symptoms associated with Alzheimer’s disease.
The amount used and how often it is taken depend on the purpose of treatment and are agreed with a doctor or pharmacist. Aricept is taken orally as tablets, with the treatment plan commonly involving gradual adjustment so that tolerance can be assessed.
Practical administration points include:
Donepezil treatment is often continued while the prescriber and family observe a meaningful cognitive or functional benefit. The duration is not fixed for every patient. Continued treatment may be reconsidered if adverse effects become troublesome or if cognitive and functional decline progresses despite therapy.
One mistake seen in practice is judging the treatment after only a few days. The medicine does not work like a sedative or pain reliever. Its role is assessed through memory testing, behaviour, communication, and everyday function over a longer period.
Aricept contains donepezil, the active ingredient. Donepezil is a reversible, centrally acting cholinesterase inhibitor used to support cognitive symptoms associated with Alzheimer’s disease. It increases acetylcholine activity in the brain and is taken orally as tablets. The amount and frequency are agreed with a doctor or pharmacist.
Donepezil belongs to the cholinesterase inhibitor class. It inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine in synaptic spaces between nerve cells. Higher acetylcholine availability can improve cholinergic signalling in brain regions involved in memory and attention.
The medicine acts reversibly. It does not create new neurons, dissolve amyloid plaques, or stop the biological process of Alzheimer’s disease. Its purpose is more limited: to increase the availability of a neurotransmitter that may still support communication between surviving nerve cells.
The effect is central rather than limited to one body system. Acetylcholine also influences the gastrointestinal tract, heart-rate regulation, bladder function, and muscle activity. This explains why nausea, diarrhoea, appetite changes, dizziness, slow pulse, or muscle cramps can occur in some patients.
Aricept contains donepezil, a reversible acetylcholinesterase inhibitor. Donepezil is used in the management of Alzheimer’s disease, the most common cause of dementia worldwide. The medicine may support cognitive performance and daily activities, although it does not remove the underlying disease or restore lost brain cells. Clinical benefits are assessed over time rather than after a single tablet. [1]
Alzheimer’s disease involves progressive changes in the brain, including abnormal accumulation of amyloid plaques, tau-related pathology, nerve-cell dysfunction, and loss of neuronal connections. These changes reduce communication between brain cells. Acetylcholine is one of the neurotransmitters involved in attention, learning, and memory, so preserving its activity can help maintain remaining cognitive function.
Aricept is used for Alzheimer’s disease rather than every type of dementia. A specialist or prescriber may assess memory symptoms, functional decline, other illnesses, current medicines, and the possibility of alternative causes before treatment begins.
Patients may notice changes in several areas:
The response differs from person to person. Some patients show measurable stabilisation rather than a dramatic improvement. That distinction matters because a slower decline may represent a meaningful treatment benefit in progressive dementia.
Several errors can reduce tolerability or make the treatment appear ineffective:
A family member may also misjudge benefit by focusing only on memory. The ability to maintain dressing, eating, communication, or familiar household tasks can provide more useful evidence of day-to-day function.
Aricept is not suitable for everyone. A prescriber should review the following factors before treatment begins:
Donepezil can interact with medicines that slow the heart, including some beta blockers and certain calcium-channel blockers. Medicines that increase gastrointestinal bleeding risk, such as non-steroidal anti-inflammatory drugs, may require review in patients with ulcer risk. Anticholinergic medicines can oppose the intended pharmacological effect.
Some medicines alter donepezil metabolism. Strong CYP3A4 or CYP2D6 inhibitors may increase exposure, while enzyme inducers may reduce it. The prescriber should also know about medicines that prolong the QT interval because donepezil has been associated with cardiac repolarisation concerns in susceptible patients.
Pregnancy and breastfeeding require an individual assessment because Aricept is primarily used in older adults, while robust pregnancy data are limited. Anaesthetists also need to know about donepezil before surgery because cholinesterase inhibitors may affect neuromuscular-blocking medicines.
Aricept is NOT for you if you have a previous allergic reaction, clinically significant bradycardia, unexplained fainting, or another contraindication listed below.
Nausea, vomiting, and diarrhoea are among the gastrointestinal effects associated with donepezil. These symptoms may appear after initiation or dose increases and can improve as the body adjusts. Appetite loss, abdominal discomfort, weight reduction, dizziness, headache, insomnia, abnormal dreams, fatigue, and muscle cramps may also occur.
Common tolerability problems include:
Taking the medicine with food may reduce stomach upset for some people, though the dosing plan should remain consistent. Persistent vomiting or diarrhoea can cause dehydration, weakness, and falls, especially in older adults. The Cochrane evidence review on donepezil reports that gastrointestinal effects are among the adverse events that can limit tolerability during treatment. [1]
Urgent medical assessment is needed for fainting, a very slow heartbeat, chest pain, severe breathing difficulty, black stools, vomiting blood, severe abdominal pain, or a seizure. Donepezil can increase vagal effects on heart-rate conduction and may worsen susceptibility to bradycardia or heart block in vulnerable patients.
Rare but clinically significant reactions include:
A patient who develops fainting after treatment begins should not simply attribute it to age or dehydration. Heart-rate effects, interacting medicines, and other causes require assessment.
Donepezil, rivastigmine, and galantamine all increase cholinergic activity, but their pharmacology and practical use differ. The choice depends on the diagnosis, treatment history, swallowing ability, adverse effects, kidney or liver function, and the prescriber’s assessment.
| Active ingredient | Main pharmacological distinction | Practical consideration |
|---|---|---|
| Donepezil | Reversible acetylcholinesterase inhibition with prolonged exposure | Oral tablets; simple daily routine |
| Rivastigmine | Inhibits acetylcholinesterase and butyrylcholinesterase | Oral and transdermal options; skin treatment may help when swallowing is difficult |
| Galantamine | Acetylcholinesterase inhibition with additional nicotinic receptor modulation | Oral treatment; kidney and liver function influence suitability |
Rivastigmine may cause gastrointestinal symptoms and can produce skin reactions when delivered through a patch. Galantamine also requires attention to gastrointestinal tolerance and renal or hepatic impairment. Donepezil’s longer half-life can simplify administration, but adverse effects may take longer to clear after a dose change.
These medicines are not interchangeable tablet-for-tablet. A switch requires a planned schedule. Abrupt changes can cause treatment interruption, renewed side effects, or confusion about which medicine is being taken.
In clinical practice, doctors usually set a realistic target: maintaining function for as long as possible, rather than expecting a cure. Families may notice improved engagement, fewer repeated questions, or better participation in established routines. Other patients show little visible change but appear to decline more slowly.
A physician will usually review:
Treatment response should be reassessed when the person’s daily function changes. A memory score alone should not determine continuation. The European Medicines Agency recognises cholinesterase inhibitors as symptomatic treatments whose benefits and risks must be reviewed in the context of the individual patient. [2]
A practical clinical point is that a stable routine can make treatment easier to evaluate. If several medicines are changed at once, it becomes difficult to identify which change caused nausea, sleep disturbance, dizziness, or confusion.
A missed dose should not be replaced by taking extra tablets. The usual approach after one missed dose is to return to the planned schedule, while repeated missed doses may require a new titration plan. The FDA's 2023 prescribing information treats dose adjustment and interruption as clinical decisions, especially when treatment has been stopped for several days. A pharmacist or prescriber can determine the safest restart plan for the individual patient.
The prescriber should know about fainting, slow pulse, heart block, stomach ulcers, gastrointestinal bleeding, seizures, asthma, chronic obstructive pulmonary disease, urinary obstruction, liver disease, pregnancy, and planned surgery. A full medicine review should include beta blockers, calcium-channel blockers, anti-inflammatory medicines, anticholinergic drugs, and medicines that affect CYP enzymes or cardiac rhythm. Medsafe's 2023 safety information supports careful review of cardiovascular, gastrointestinal, respiratory, and interaction risks before treatment. These details help determine whether donepezil is suitable and how monitoring should be arranged.
Donepezil has a long half-life, so a dose continues to contribute to drug exposure beyond the day it is taken. The medicine is designed for regular administration rather than occasional use for an immediate memory boost. EMA product information from 2009 describes gradual accumulation and sustained exposure during repeated treatment. Clinical benefit is assessed over weeks or months through cognition, function, behaviour, and carer observations rather than through a short-term sensation after one dose.
Aricept is intended for Alzheimer’s disease in adults, and routine use in people under 18 is not established. Childhood and adolescent memory problems have different causes and require a separate diagnostic approach. WHO's 2023 dementia guidance places Alzheimer’s disease within an older-adult clinical context, rather than recommending donepezil for general developmental or school-related memory concerns. A child or teenager should not receive Aricept unless a specialist has made a specific, documented decision.
Donepezil may cause dizziness, fainting, fatigue, sleep disturbance, blurred vision, or muscle cramps, and these effects can impair driving or machinery work. The risk may be greater after starting treatment or changing the dose. The New Zealand Medicines and Medical Devices Safety Authority, Medsafe, issued advice in 2023 that patients should consider medicine-related impairment when performing tasks requiring alertness. Driving should be avoided if dizziness, fainting, unusual sleepiness, or impaired concentration occurs.
Older adults are the main population treated for Alzheimer’s disease, but age increases vulnerability to dehydration, weight loss, falls, slow pulse, and medicine interactions. Renal and hepatic function, nutrition, cardiovascular history, and the complete medicine list should be reviewed during follow-up. The EMA’s 2009 clinical framework for dementia treatment supports individual benefit-risk assessment rather than an age-only decision. Older patients may benefit from a simpler daily routine, carer support, and regular monitoring of appetite, weight, pulse, and everyday function.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
The first week brought nausea and less appetite. That settled after the adjustment period. My mother seemed more willing to join conversations, although her memory was still poor.
Nelson Three months 25 Oct 2026Sleep became restless after the tablets were moved to the evening. The timing was changed and the dreams were less troublesome. I did not see a quick memory improvement, so the family started tracking everyday tasks instead.
Palmerston North Six weeks 4 Nov 2026Aricept seemed to help with familiar routines for a while. There was also weight loss and occasional dizziness, which meant the treatment needed a proper review rather than simply continuing unchanged.
Queenstown Five months 6 Oct 2026
